Table 2.

Hemodynamic data before and after SGLT2 inhibitor treatment.

	Before administering SGLT2 inhibitor	After administering SGLT2 inhibitor	p‐value
Number	10	10
Echocardiography
LVEF (%)	68.9 ± 3.2	69.0 ± 5.4	0.864
LVDd (mm)	44.1 ± 4.1	45.7 ± 3.8	0.163
LA (mm)	34.3 ± 7.4	37.6 ± 7.5	0.228
E/e’	8.3 ± 2.9	10.5 ± 3.5	0.246
RVFAC (mm)	39.4 ± 2.7	38.4 ± 6.8	0.479
TAPSE	22.2 ± 3.1	21.2 ± 4.6	0.089
TRPG (mmHg)	36.9 ± 14.8	37.5 ± 13.4	0.132
MRI
LVEDVi	70.1 ± 15.3	75.7 ± 20.4	0.121
LVESVi	29.5 ± 7.5	31.0 ± 7.5	0.348
LV: GLS	−13.8 ± 2.0	−17.3 ± 2.0	0.003
LV: GRS	25.1 ± 2.6	29.3 ± 6.3	0.070
LV: GCS	−18.8 ± 2.0	−20.3 ± 3.1	0.095
RVEDVi	79.0 ± 16.9	80.9 ± 24.6	0.634
RVESVi	36.4 ± 16.1	36.7 ± 12.4	0.893
RV: GLS	−13.8 ± 2.1	−15.2 ± 3.3	0.284
Peak LA strain	−14.1 ± 2.9	−17.3 ± 5.0	0.297
Peak RA strain	−15.8 ± 5.6	−14.2 ± 5.4	0.105

Note: Paired t‐test were used for changes in parameters of echocardiography and MRI before and after treatment with SGLT2 inhibitor.

Abbreviations: GCS, global circumferential strain; GLS, global longitudinal strain; GRS, global radial strain; LA, left atrium; LA, left atrial; LV, left ventricular; LVEF, left ventricular ejection fraction; LVDd, left ventricular diameter at end‐diastole; LVEDVi, left ventricular end‐diastolic volume index; LVESi, left ventricular end‐systolic volume index; RA, right atrial; RVFAC, right ventricular fractional area change; TAPSE, tricuspid annular plane systolic excursion; TRPG, tricuspid regurgitation peak gradient.